CYP3A5酶基因多态性对阿托伐他汀调脂疗效的影响  

The effect of CYP3A5 enzyme genetic polymorphiism on atorvastatin modffying serum lipids

作　　者：邓永萍 王若伦[2] 陈智超 

机构地区：[1]广州市老人院康复科,510550 [2]广州医学院第二附属医院药学部

出　　处：《中国医药》2011年第9期1054-1055,共2页China Medicine

基　　金：广州市医药卫生科技项目（2007-YB-202）

摘　　要：目的 研究CYP3A5酶基因多态性与阿托伐他汀调脂疗效与安全性的临床效应个体差异的相关性.方法 47例高脂血症患者予阿托伐他汀片（10 mg,每日1次口服）治疗,疗程24周.分别于治疗前及疗程结束时空腹抽血检测血脂（TC、TG、LDL-C、HDL-C）肝酶及肌酸激酶水平.采用聚合酶链反应扩增及限制性片段长度多态性技术对患者CYP3A5酶基因进行分型.结果 按CYP3A5基因型分组,CYP3A5＊1组22例（包括CYP3A5＊1/＊1型2例和CYP3A5＊1/＊3型20例）,CYP3A5＊3组（即CYP3A5＊3/＊3型）25例.治疗后,2组患者TC、LDL-C、TG水平均有有明下降（P＜0.05）.CYP3A5＊3组患者的TC、LDL-C下降幅度分别为（29.82±5.25）%和（35.35±4.06）%,明显大于CYP3A5＊1组的（19.99±3.16）%和（25.84±2.31）%（均P＜0.05）.CYP3A5＊1组和CYP3A5＊3组TG下降幅度分别为（31.81±4.68）%和（34.32±4.34）%,HDL-C升高幅度分别为（4.80±1.42）%和（5.65±1.76）%,2组差异无统计学意义（均P＞0.05）.结论 CYP3A5酶基因多态性可能对阿托伐他汀调脂疗效有影响.Objective To study the correlationship between CYP3A5 enzyme genetic polymorphism and effectivity as well as security of Atorvastatin to provide reference for clinical usage. Methods Forty-seven aged patients with hypercholesterolemia were enrolled. Atorvastatin（10 mg/d） was given for treatment. All patients＇ serum level of TC, TG, LDL-C, aminotransferase and phosphocreatine before and after the 24 weeks＇ treatment were tested. PCR-RELP technique was adopted to analyze CYP3A5 enzyme gene of the patients. Results There were 22 cases who were divided in the CYP3A5 1 group（including 2 cases for CYP3A5 1/1 and twenty for CYP3A5 1/ 3） and 25 into the CYP3 A5 3 group. After Atorvastatin treatment, both group showed reduction in serum level ofTC, LDL-C, TG（P〈0.05）. The reduction amplitude of serum TC and LDL-C level of CYP3A5 3 group was （29.82 ± 5.25） % and （35.35 ± 4.06） % respectively, which was higher than that of CYP3A5 1 group [（19. 99 ± 3.16） % and （25.84 ± 2.31） %]. Conclusion CYP3A5 enzyme genetic polymorphism may influence Atorvastatin treatment.

关 键 词：阿托伐他汀 CYP3A5 基因多态性 调脂效果 

分 类 号：R589[医药卫生—内分泌]